Genomics has been a game-changer for clinical and translational research over the past decade, and has improved success in drug discovery and development. Major genomics programmes are also recognised as having stimulated significant economic return. The economic impact of the Human Genome Project in the USA has been calculated as $796 billion from a $3.8 billion investment, a return on investment of 141:1.
This session will set out an overview from a regulatory, political, patient and industry perspective the advancements that can take through the following areas:
- Improving Treatment Selection in Cancer
- Maximising Success of Diagnosis in Rare Diseases
- The Power of a Diagnosis
- Tracking a Disease Outbreak